Induction of ovulation and pregnancy [in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure]; development of multiple follicles in ovulatory patients participating in an Assisted Reproductive Technology [ART] program.
Assisted Reproductive Technologies [ART]: A starting dose of 150 to 225 IU of follitropin Beta for at least the first four days of treatment after which the dose is adjusted based on the ovarian response [maximum dose is 600 IU]. When a sufficient number of follicles of adequate size are present, the final maturation of the follicles is induced by administering hCG at a dose of 5000 IU to 10,000 IU after which the Oocyte retrieval is performed 34 - 36 later [the administration of hCG must be withheld in cases where the ovaries are abnormally enlarged on the last day of treatment in order to reduce the chance of developing OHSS.
Ovulation Indication suction
A step-wise gradually increasing dosing scheme can be used. Starting dose of 75 IU is given for up to 14 days. The dose is then increased by 37.5 IU at weekly intervals until follicular growth and/or serum estradiol levels indicate an adequate response [max. dose - 300 IU]. The patient is treated until ultrasonic visualizations and/or serum estradiol determinations indicate pre-ovulatory conditions equivalent to or greater than those of the normal individual followed by hCG, 5000 IU to 10,000 IU. If the ovaries are abnormally enlarged on the last day of follitropin therapy, hCG must be withheld during this course of treatment; this will reduce the chances of developing OHSS. Seven to ten days post-ovulation.
See product literature insert for further
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It stimulates ovarian follicular growth in those when there is no primary ovarian failure. Physiologically, FSH is required for normal follicular growth, maturation, and gonadal steroid production. Human chorionic gonadotro-pin [hCG] is given after the administration of Recombinant Human FSH when patient monitor-ing indicates that appropriate follicular development parameters have been reached. This is done to effect the final phase of follicle maturation, resumption of meiosis and rupture of the follicle in the absence of an endogenous LH surge.
To be used only under the supervision of an experienced gynaecologist;avoid possibility of over stimulation of the ovary in the course of therapy
Hypersensitivity to the drug; primary ovarian failure [as evidenced by high circulating FSH level]; ovarian cysts or enlargement not due to polycystic ovary disease; pregnancy; heavy or irregular vaginal bleeding of unknown origin; cancer of the ovary, breast, uterus, hypothalamus or pituitary gland; thyroid or adrenal dysfunction that is not controlled;
Miscarriage; Ovarian Hyperstimulation Syndrome; ectopic pregnancy; abdominal pain; pain at the injection site; vaginal haemorrhage; dizziness; tachycardia; dyspnea; tachypnea; febrile reactions; flu-like symptoms including fever, chills musculo-skeletal aches, joint pains, nausea, headache and malaise; breast tenderness; dermatological symptoms.